Compare Snowflake Inc (SNOW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs TransMedics Group Inc — how do they compare? Snowflake Inc trades at $331.59 (market cap $116.95B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Snowflake Inc is far larger — about 39× TransMedics Group Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SNOW | TMDX | |
|---|---|---|
Market Cap | $116.95B | $3.00B |
Sector | Technology | Technology |
52-Week High | $356.47 | $150.42 |
52-Week Low | $121.11 | $61.99 |
Enterprise Value | $117.37B | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $335.50, down 0.5% on the day, following a strong earnings-driven rally. The stock exhibits bullish technical signals with support at $331 and resistance at $340. Revenue growth accelerated to 37% year-over-year in Q2 2026, with consistent earnings beats, though profitability remains negative with a net margin of -20.07%. Recent news highlights AI-driven demand boosting product revenue and customer adoption.
Outlook is positive with 81% analyst buy ratings and a $430.10 price target, reflecting optimism around AI data cloud growth. Key risks include high valuation (P/S 21.25), persistent losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
